Floatz logo

trc102

Recurrent Marginal Zone Lymphoma

Case Comprehensive Cancer CenterPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

106 Active assets in the Recurrent Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
VINCRISTINE SULFATE
Mayo Clinic
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

trc102 is also rated in:

lung large cell carcinomaDormant
B
Indicative ·
60 / 100
View asset →
neoplasmDormant
B
Indicative ·
59 / 100
View asset →
lung adenocarcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →